Last reviewed · How we verify

NCT07135089: INSIST-IT2

Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban

Recruiting now Phase 3 Last updated 9 December 2025
What this trial tests

Phase 3 trial testing Intravenous tirofiban before endovascular thrombectomy in Stroke, Ischemic in 870 participants. Currently enrolling.

Timeline
13 November 2025
Primary endpoint
30 September 2027
30 December 2027

Quick facts

Lead sponsorGeneral Hospital of Shenyang Military Region
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment870
Start date13 November 2025
Primary completion30 September 2027
Estimated completion30 December 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

General Hospital of Shenyang Military Region

Who can join

18 and older, any sex, with Stroke, Ischemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke, Ischemic

Currently open trials in the same condition.

Other General Hospital of Shenyang Military Region trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07135089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing